CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.
B Cell Lymphoma|B Cell Leukemia
BIOLOGICAL: CD19 CARvac T cells
Number of participants with dose limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, 28 days|Type of dose-limiting toxicity (DLT), 28 days|Number of participants with adverse event by severity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, 2 years
Overall Response Rate (ORR), Assessment of morphologic complete remission (CR), complete remission with incomplete recovery of counts (CR1), no residual disease as analyzed by flow cytometry analysis, and molecular remission by molecular studies, 1 year|Progression-free survival (PFS), 1 year|Overall survival, 1 year
CD19 CARvac is a chimeric antigen receptor immunotherapy treatment designed to treat